You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4257496 GRPR radiopharmaceutical with or without standard of care therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer. Your tumor must be positive for gastrin-releasing peptide receptor (GRPR). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496 is a radiopharmaceutical that targets GRPR. A radiopharmaceutical is a type of therapy that combines a molecule that targets cancer cells with a radioactive molecule that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Gastrin Releasing Peptide Receptor (GRPR) is a G protein coupled receptor activated by the peptide gastrin-releasing peptide (GRP), which regulates various bodily functions, including gastrointestinal activity and central nervous system processes. GRPR plays a role in normal functions like hormone release and smooth muscle contraction.</li> <li class="seamTextUnorderedListItem">Standard of care options in this trial are fulvestrant (Faslodex®), imlunestrant (Inluriyo®), capecitabine (Xeloda®), abemaciclib (Verzenio®) and aromatase inhibitors- letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07114601' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: Radiopharmaceuticals</a> </li></ul>
1

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
Icon

Nearest Location:
27 miles
Stanford University Medical Center
Stanford, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07114601

Icon

Phase I

HELP GUIDE
HELP GUIDE